Healthcare / BiotechnologyKOSDAQ
$13790.00
-750.00 (-5.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-9.9B · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$90.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-62.3%
↓Gross Margin
100.0%
↑Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+76.4%
FCF CAGR
—
FCF margin
-662.9%
FCF / Net income
1.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.41B · net income $-15.37B · FCF $-15.95B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.41B | $2.41B | $1.95B | $1.59B | $438.2M |
| Net Income | $-15.37B | $-15.37B | $-11.25B | $-38.69B | $-24.11B |
| EBITDA | $-13.93B | $-13.93B | $-7.04B | $-31.73B | $-18.40B |
| EPS | -2517.00 | -2517.00 | -2691.00 | -13563.00 | -8413.00 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -673.2% | -673.2% | -626.4% | -615.6% | -2407.9% |
| Net Margin | -638.6% | -638.6% | -575.8% | -2431.6% | -5501.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.53 | -0.06 | -0.11 |
| Current Ratio | 2.01 | 2.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.95B | $-15.95B | $-9.93B | $-8.27B | $-10.32B |
| Returns | |||||
| ROE | -62.3% | -62.3% | -73.4% | 50.0% | 60.9% |
| Valuation | |||||
| P/B | 3.41 | 3.41 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 23.2% | 23.2% | 22.8% | 263.1% | — |
| EPS Growth | 6.5% | 6.5% | 80.2% | -61.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-66.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2691.00 → -2517.00
Residual
-66.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.